T1	Participants 10 29	antipsychotic drugs
T2	Participants 585 658	risperidone (N=16), olanzapine (N=18) and low doses of haloperidol (N=18)
T3	Participants 725 790	large and heterogeneous sample of schizophrenia spectrum patients
T4	Participants 900 964	group of 45 healthy volunteers was also longitudinally evaluated
